论文部分内容阅读
背景:1岁以下婴儿是侵袭性脑膜炎球菌病(IMD)的最大危险人群。4价脑膜炎球菌结合疫苗有预防血清型A、C、W和Y引起IMD的潜力。此次多国、标签公开、随机、平行组、多中心的临床Ⅲb期研究评价了4价脑膜炎球菌结合疫苗MenACWYCRM当伴随健康婴儿的常规疫苗接种时的安全性。方法 :2月龄婴儿按3∶1在2、4、6和12月龄接受MenACWY-CRM和常规疫苗或单独常规疫苗。
Background: Infants under 1 year old are the most at-risk populations of invasive meningococcal disease (IMD). The 4 meningococcal conjugate vaccine has the potential to prevent the serotypes A, C, W and Y from causing IMD. The multicenter, randomized, parallel-group, multicentre clinical Phase IIIb study evaluated the safety of the 4-valent meningococcal conjugate vaccine MenACWYCRM when administered routinely to healthy infants. Methods: 2-month-old infants received MenACWY-CRM at either 2, 4, 6 and 12 months at 3: 1 with either conventional or separate vaccines.